| Next 10 |
Ad
OTLK Articles Outlook Therapeutics Inc.
home / stock / otlk / otlk articles
Articles | Outlook Therapeutics Inc. (NASDAQ:OTLK)
-
Live video webcast on Tuesday, June 18th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTL...
-
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the firs...
-
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...
-
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...
-
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded down 0.49% to 39,585.67...
-
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adj...
-
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0.54% to 39,565.50 whil...
-
Outlook Therapeutics Inc (NASDAQ:OTLK) shares are trading higher after the Committee for Medicinal Products for Human Use of the European Medi...
-
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...
Stock Information
Get OTLK Alerts
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
Ad
-
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of...
-
2024-11-29 06:30:01 ET BTIG analyst issues BUY recommendation for OTLK on November 29, 2024 11:02AM ET. The previous analyst recommendation was Buy. OTLK was trading at $1.7591 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
-
Final efficacy data expected in January 2025 Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the Un...